Chardan Capital Reiterates a Buy Rating on Rocket Pharmaceuticals (RCKT)
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Rocket Pharmaceuticals (RCKT), with a price target of $33.00. The company’s shares closed last Monday at $18.26.
According to TipRanks.com, Livshits is a 3-star analyst with an average return of 2.5% and a 39.3% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Crispr Therapeutics AG, and Intellia Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Rocket Pharmaceuticals with a $33.00 average price target, which is a 76.1% upside from current levels. In a report issued on March 5, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.59 and a one-year low of $10.76. Currently, Rocket Pharmaceuticals has an average volume of 434.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms.